Hepatitis B Treatment Breakthrough: Triple Oral Medication Enters Phase II Clinical Trials 

The world's first triple oral therapy, combining the innovative drugs GST-HG131 and GST-HG141, has been approved for Phase II clinical trials aimed at improving the cure rate for chronic hepatitis B patients. The National Medical Products Administration (NMPA) has fast-tracked approval for this therapy, showing strong support for innovative drugs. Compared to existing injectable medications, this oral therapy offers significant advantages in terms of convenience and cost control. The development focuses on "functional cure," meaning that after treatment, the viral load remains below detectable levels, and antibody levels in the body are normal. This research by Guangshengtang is expected to break through the bottleneck in hepatitis B treatment and contribute to the global goal of eliminating viral hepatitis.